Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

COVID-19 Impact on Molecular Diagnostics, Immunoassays, Vaccines, Telehealth and Other Areas

Published

on

Dublin, April 24, 2020 (GLOBE NEWSWIRE) — The “COVID-19 Update: Molecular Diagnostics, Immunoassays, Vaccines, Telehealth and Other Areas” report has been added to ResearchAndMarkets.com’s offering.
For years, the analyst has covered the fields of molecular diagnostics, immunoassays, vaccines, and telehealth – these all find themselves both sought-after and challenged during the current COVID-19 crisisThis report provides trending developments, company announcements, and analysis from the analysis team on the fast-breaking events in the COVID-19 epidemic.Particular sections address the most important market changes:Molecular Diagnostics: It’s important to note that the entire molecular testing concept originated in the midst of a crisis, at that time of the AIDS crisis, and has since been brought to bear on a number of emerging and mature infectious disease categories. COVID-19 has seen the molecular in vitro diagnostics (IVD) industry bring out its best efforts in terms of fast test RT-PCR tests for their systems, point of care solutions, syndromic tests, high throughput systems and surge production on badly needed kits.Immunoassays: Never have immunoassays been of such worldwide attention, as antibody tests are greatly sought. With this, come concerns about accuracy levels on broad populations and greater knowledge about development times. There are now immunoassays in development. We track these efforts and provide commentary on the role of these tests in a threat so far dominated by molecular diagnostics.Vaccines: The analyst look at the vaccines in development and the struggles with vaccine discovery and manufacturing in other pandemics. Companies developing vaccines are featured.Other Traditional IVDs: With many hospitals shut down across the globe, what is the impact and expected future of standard in vitro diagnostic testing? – from company statements made both publicly and directly to the analyst.Remote Patient Monitoring: Already a healthcare trend that was catching on but perhaps struggling to convince payors of its critical necessity, remote patient monitoring, and telehealth transformed overnight with social distancing policies and relaxed HIPAA rules. But will market players be crowded out by traditional phone and web video companies?This report does not seek to provide a data-driven market assessment due to the rapidly-changing situation but does provide analyst commentary that may assist customers needing to work out models. Some of the market estimates provide foundational bases on which to judge potential market impact. Commentary and analysis from the analysts who have studied markets in some cases for decades add understanding to the current, often chaotic, market atmosphere. Further publications and surveys from the analyst will provide additional market impact data.No one company has the solution to COVID-19. Multiple companies have solutions to one problem or part of the solution, and companies are partnering to build strength and distribute products.Key Topics Covered
Chapter One: SARS-Cov-2 Recent DevelopmentsMolecular Testing, So Far, Remains At ForefrontAntibody SARS-Cov-2 Tests Move ForwardOverall Diagnostics Testing Taking a HitWhen Will Surgeries – and Related Diagnostic Testing – Resume?Asymptomatic and Presymptomatic Spread Will Focus Attention on TestingContinuous Introduction and Authorization of New Test ProductsMolecular DXImmunoassaysSpain Provides Example of Downside of Early Serology TestAncillary/Secondary Covid-19-Related TestsU.S. Government ResponseCongress Passes Cares ActHHS Awards $100M to Deal With Coronavirus, Including TestingBarda Funding for POC, Panels and Automated TestsWhite House Pushes DiagnosticsCovid-19 Threat Makes for Odd Timing of Valid ActBackgroundDefining SARS-Cov-2Naming the VirusOrigins of SARS-Cov-2A Unique Molecular BackboneFDA Provides Reference Sequence Data for SARS-Cov-2Countermeasures in DevelopmentWill We See Fundamental Change in IVD?Chapter Two: Molecular Diagnostics and SARS-Cov-2The Molecular Diagnostics Industry is Large and CapableRapid Ramp Up After Early StumblesFast EUAs as FDA Moves to Speed Availability of Covid-19 TestsTwist’s SARS-Cov-2 Quality Controls Added to FDA MaterialsTest ApprovalsTable: US FDA EUAs as of April 1, 2020Mesa Handheld Mdx Test ShipsSyndromic Approach to Covid-19: QiagenAbbott Id Now Becomes National Symbol of Poc ResponseLuminex Coronavirus Panel Gets FDA Emergency AuthorizationBGI Gets EUA for Rt-PCR Coronavirus TestQuidel Receives Expanded ApprovalNeumodx Coronavirus Test Gets Emergency AuthorizationT2 Adds Coronavirus Test to Panels, Per Health Network DealPerkinelmer Gets Regulatory Nod in the U.S. for Coronavirus TestRoche Offers Multiple Commercial KitsThermo Fisher Gets CE Mark for the Taqpath Covid-19 Rt-PCR Test KitMesa Biotech Gets Emergency Authorization for Poc Coronavirus TestFluxergy Seeks Emergency Authorization for 1-Hour Coronavirus TestGenetic Signatures Seeks CE Mark for Coronavirus DiagnosticEmerald Organic, Todos Medical Team on Covid-19 TestsBruker, Primer Design Sign European Distribution Deal for Coronavirus TestImpact of Large Systems and Small Poc SystemsMolecular Point of CareMolecular POC Vs. ImmunoassaysChapter Three: BottlenecksPractical Challenges and Scaling of Test ResourcesTest Equipment and Worker Ppe Remain An IssueJama Network Calls for Creative Ideas for Increasing Ppe SupplyWhy SARS 2.0 is More Difficult to ControlTable: Covid-19 Case Severity ScaleSARS-Cov-2 Replication in Upper Respiratory Track Seen as CulpritHais a Worryare Coronavirus Patients With Negative Throat Swabs Truly Virus-Free?Patients May Continue to Shed Virus After Symptom ClearanceViral Load/ Symptom Connection: Conflicting StudiesMPOC S are Approved; Full Impact Yet to Be SeenFigure: FDA EUA Tests for Covid-19 by Testing TypeQiagen Says It Ramped Up Production to Meet Shortage of Rna Extraction KitsChapter Four: Covid-19 ImmunoassaysAntibody-Based Testing Taking ShapePolicy D PathwayCEllex ApprovalBiomedomicsGetting Better Guidance on Test QualitySerology Test NotificationsChapter Five: Other Test Categories Impact: Critical Care, ChemistriesCritical Care AnalysisBlood GasCritical Care Analytes: Bilirubin, Bun, GlucoseOther Covid-19-Related TestsAKI TestingChapter Six: Vaccines and SARS-Cov-2Early Efforts and a First Trial DoseJ&J Seeks to Release Covid-19 Vaccine by 2021Dod Grant Accelerates SARS-Cov-2 Vaccine ManufacturingDynavax, Clover Partner for Protein-Based Covid-19 VaccineAnalysts: Technology, Not Demand ChallengeProduction Consideration3D Atomic Scale Map Could AId VaccinesChapter Seven: Boost for Remote Patient Monitoring Seen in SARS-Cov-2 CrisisCongressional ActionHippa Penalties RelaxedUnique Opportunities in Telehealth/TelemedicineCompanies in the MarketRecent DevelopmentsChapter Eight: a Role for Artificial Intelligence (AI)IntroductionWhite House Urges Researchers to Use AI to Analyze Coronavirus PapersDiagnostic ApplicationsSouth Korean Firm Blends AI and Portable X-Ray Testing to Power Up Covid-19 PCRPersivia Releases AI-Driven Ruleset to Detect Covid-19Philips Intellisite Pathology SolutionSurgisphere Rapid Test Uses AI to Diagnose Covid-19Biofourmis’ AI-Powered Remote Monitoring Platform to Fight Covid-19AI as An AId in the Development of Covid-19 TherapiesChapter Nine: Therapeutics and Covid-19FDA’s Coronavirus Treatment Acceleration Program (Ctap)Snapshot for Developing TherapeuticsExamples of CTAP in ActionSupport for CTAPSelected Therapeutic ApproachesDrug RepurposingCar-T Support Therapeutic Finds Possible Use in Covid-19Kleo, Green Cross Collaborate on Covid-19 Nk Combination TherapyGeneration Bio, Vir Partner for Mabs Against Covid-19Xencor, Vir Partner on Covid-19 Antibodies ResearchFrontera Supercomputer AIds Covid-19 Drug DevelopmentHydroxychloroquineChapter Ten: Respiratory Equipment in Extreme DemandVentilatorsCPAP Devices and Covid-19 Patient UsageCPAP as an Emergency Ventilator?Risk of Virus Spread and Possible SolutionsPulse OximetersRecent EU ActivityCares ActDefense Production ActChapter Eleven: Research Laboratory Operations ImpactedNIH Shifts Noncritical Research to MaintenanceSurvey: Nearly Half of All Life Science Labs Around the World are Currently ClosedSurvey: Covid-19 Causes Long-Term Disruptions to Clinical TrialsCompanies Mentioned
AbbottAmaro Lab of the University of California (UC), San DiegoAvellino Lab USABGIBioFireBiofourmisBoston ScientificBrukerCepheidCloverCredo Diagnostics BiomedicalDiagnostics for the Real WorldDiaSorin MolecularDynavaxEmerald OrganicEpiGentekFluxergyGE HealthcareGeneration BioGenetic SignaturesGenMark DiagnosticsGilead ScienceGreen CrossHackensack Meridian Health, Center for Discovery and Innovation’s (CDI)Henry ScheinHiberGene DiagnosticsHologicJLK InspectionJohnson & Johnson (J&J)KleoLaboratory Corporation of America (LabCorp)LuminexMedtronicMesa BiotechMobidiagMolbio DiagnosticsNeuMoDxPerkinElmerPersiviaPhilips MedicalPrimer DesignQiagenQuantuMDxQuestQuidelRocheSurgisphereT2 BiosytemsThermo FisherThermoGenesisTodos MedicalVirWadsworth Center, New York State Department of HealthXencorFor more information about this report visit https://www.researchandmarkets.com/r/1anzkzResearch and Markets also offers Custom Research services providing focused, comprehensive and tailored research.CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Securitas AB Interim Report Q1 2024 January-March

Published

on

securitas-ab-interim-report-q1-2024-january-march

STOCKHOLM, May 8, 2024 /PRNewswire/ — 

January–March 2024
Total sales MSEK 39 260 (37 751)Organic sales growth 7 percent (12)Real sales growth within technology and solutions 7 percent (77)Operating income before amortization MSEK 2 357 (2 180)Operating margin 6.0 percent (5.8)Earnings per share SEK 1.84 (1.66)Earnings per share before IAC, SEK 2.12 (2.03)Net debt/EBITDA ratio 2.9 (3.3*)Cash flow from operating activities –15 percent (9)*The comparative is adjusted and includes STANLEY Security’s 12 months adjusted estimated EBITDA.
Comments from the President and CEO
“Continued operating margin improvement in line with strategy”
The operating margin improvement continued in the first quarter to 6.0 percent (5.8), driven by a strong performance in our North American operations. Ibero-America also developed well, while Europe was weak primarily due to challenges within the airport security business. The Group’s operating margin improved both in security services and in technology and solutions. 
Organic sales growth was 7 percent. Real sales growth in our technology and solutions business was also 7 percent in the first quarter, negatively impacted by the divestment of Securitas Argentina in July 2023. 
The integration of STANLEY Security continued to progress, realizing further cost synergies although these were partly offset by operational cost increases from the ongoing system and support transitions that are progressing according to plan. Our combined offering is gaining increased interest and appreciation from both existing and new clients, which presents good opportunities for deeper client partnerships and commercial synergies in our business. 
The first quarter is our weakest cash flow quarter due to seasonality. As ­expected, the operating cash flow was lower than last year due to the strong net working capital position at year-end 2023, and as the quarter ended with the Easter holiday impacting collections. We remain with strong cash flow focus across the organization to ensure a strong 2024 outcome.
SHAPING SECURITAS FOR LONG-TERM SUSTAINABLE SHAREHOLDER VALUE
The overall message at our recent Investor Day in March was how we shape Securitas for long-term sustainable shareholder value. The core to that execution is operational value creation through growth in technology and solutions, security services portfolio profitability, cost efficiency and digital innovation. 
We have invested substantially in our technology capabilities and in the transformation programs in the past few years to support the value creation, and we will continue to invest in a balanced way to ensure that our business has the capability to execute on the strategy. Another part of our strategy execution is to continuously assess our business mix and presence to further sharpen our performance and competitive position. 
I have met with a number of local and global clients in the US, Asia and Europe during the last few months and have received very positive feedback on the new Securitas we are creating. The clients are looking for a security partner with strong presence, tech­nol­ogy and data capabilities. In addition to recent contract wins, the pipeline of commercial opportunities is very promising. We are piloting a new integrated Technology and Guarding services concept for broader roll-out together with one global client. 
The strategic transformation of Securitas is on the right path and we are committed to achieve our target of 8 percent operating margin by the end of 2025. With our strong offering we will solidify our position as the leading security solutions company. 
Magnus AhlqvistPresident and CEO
PRESENTATION OF THE INTERIM REPORT
Analysts and media are invited to participate in a telephone conference on May 8, 2024, at 9.30 a.m. (CEST) where President and CEO Magnus Ahlqvist and CFO Andreas Lindback will present the report and answer questions. The ­telephone conference will also be audio cast live via Securitas’ website www.securitas.com.
To follow the audio cast of the telephone conference via the web, please follow the link www.securitas.com/en/investors/financial-reports-and-presentations/
A recorded version of the audio cast will be available at www.securitas.com/en/investors/financial-reports-and-presentations/ after the telephone conference.
For further information, please contact:Micaela Sjökvist, Vice President, Investor Relations +46 76 116 7443
ABOUT SECURITAS
Securitas is a world-leading safety and security solutions partner that helps make your world a safer place. Almost nine decades of deep experience means we see what others miss. By leveraging technology in partnership with our clients, ­combined with an innovative, holistic approach, we’re transforming the security ­industry. With approximately 341 000 employees in 44 markets, we see a different world and ­create sustainable value for our clients by protecting what matters most – their people and assets.
Group financial targets
Securitas has four financial targets:
8–10 percent technology and solutions annual average real sales growth8 percent Group operating margin by year-end 2025, with a >10 percent ­long-term operating margin ambitionA net debt to EBITDA ratio below 3.0xAn operating cash flow of 70–80 percent of operating income before ­amortizationSecuritas AB (publ.)P.O. Box 12307, SE-102 28 Stockholm, Sweden
Visiting address:Lindhagensplan 70Telephone: +46 10 470 30 00 Corporate registration number: 556302–7241www.securitas.com
This is information that Securitas AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 a.m. (CEST) on Wednesday, May 8, 2024.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/securitas/r/securitas-ab-interim-report-q1-2024-january-march,c3974967
The following files are available for download:
https://mb.cision.com/Main/1062/3974967/2784696.pdf
Q12024_eng_final
 

View original content:https://www.prnewswire.co.uk/news-releases/securitas-ab-interim-report-q1-2024-januarymarch-302139340.html

Continue Reading

Artificial Intelligence

TXOne Networks, Leader in Cyber-Physical Systems (CPS) Security, Raises $51 Million in Total in Series B Extension Round Funding

Published

on

txone-networks,-leader-in-cyber-physical-systems-(cps)-security,-raises-$51-million-in-total-in-series-b-extension-round-funding

Significant funding round validates TXOne Networks’ capabilities and vision for securing industrial control systems (ICS) and operational technology (OT) environments
TAIPEI, May 8, 2024 /PRNewswire/ — TXOne Networks, a leader in Cyber-Physical Systems (CPS) security, today announced a significant achievement of securing $51 million in its Series B extension round of financing. In addition to TGVest Capital, the lead investor of the B round, Pegatron Group, CDIB Capital Group and CDIB-Innolux  II L.P. are continuing to invest. New investors include the Taiwania Capital and Applied Ventures ITIC Innovation Fund, L.P. (AVITIC), a joint fund of Applied Ventures, LLC and ITIC-Taiwan (Industrial Technology Investment Corporation).

TXOne Networks completed its Series A financing in August 2021 and announced Series B financing in August 2022.
TXOne Networks works with both leading manufacturers and critical infrastructure operators to develop practical, operations-friendly approaches to cyber defense of industrial control systems (ICS) and operational technology (OT) environments. With TXOne Networks, companies in diverse OT verticals implement tailored defense, including the adoption of advanced threat detection and response measures, to effectively counter ransomware and other emergent strategic threats and protect assets for their entire lifecycle. TXOne Networks secures the operations of more than 3,600 organizations globally in industries including semiconductors, automotive, pharmaceutical, food and beverage, public transportation, utilities, electronics, healthcare, mining and metals, oil and gas, and aerospace.
“We are impressed that the ‘OT Zero Trust’ approach that TXOne Networks pioneered goes beyond the limitations of traditional cyber defense to safeguard operations and revenues, as well as its continuous efforts to streamline management, reduce security overhead and more quickly resolve challenges,” said DC Cheng, Chairman with TGVest Capital. “This makes TXOne Networks a unique player in the global cybersecurity landscape, and we are happy to partner with the company for its continuous future growth.”
Added Dr. Terence Liu, TXOne Networks chief executive officer: “The successful procurement of $51 million in this extension round marks a significant achievement for the company and underscores the confidence and trust of our investors in TXOne Networks’ vision and potential.” 
In April 2024, TXOne Networks announced its latest innovative CPS protection platform, the SageOne central management console. The new TXOne Networks platform delivers management of the CPS attack surface across the OT environment, combines advanced technologies with a user-friendly interface for securing critical infrastructures and enables integrated lifecycle protection. 
CRN in April 2024 recognized TXOne Networks among its list of “The 10 Coolest IoT Security Companies.”
Follow TXOne Networks on Blog, Twitter, and LinkedIn.
About TXOne Networks
TXOne Networks offers cybersecurity solutions that ensure the reliability and safety of industrial control systems and operational technology environments. TXOne Networks works together with both leading manufacturers and critical infrastructure operators to develop practical, operations-friendly approaches to cyber defense. TXOne Networks offers both network-based and endpoint-based products to secure the OT network and mission-critical devices using a real-time, defense-in-depth approach. www.txone.com 
Photo – https://mma.prnewswire.com/media/2406736/Dr__Terence_Liu__CEO___Co_Founder_TXOne_Networks.jpg

View original content:https://www.prnewswire.co.uk/news-releases/txone-networks-leader-in-cyber-physical-systems-cps-security-raises-51-million-in-total-in-series-b-extension-round-funding-302138357.html

Continue Reading

Artificial Intelligence

Tanmyah to Unify Management Processes & Boost Investment Value with Yardi Cloud Technology

Published

on

tanmyah-to-unify-management-processes-&-boost-investment-value-with-yardi-cloud-technology

Property management company to utilise Yardi’s end-to-end solution to strengthen its commercial operations & enhance efficiency across the Kingdom of Saudi Arabia 
JEDDAH, Saudi Arabia, May 8, 2024 /PRNewswire/ — Advanced Development Real Estate Investments (Tanmyah), recognised as one of the early pioneers in property management and development brokerage across Saudi Arabia, is set to improve its commercial property management operations and tenant experience with Yardi®. 

The Yardi® Commercial Suite will allow Tanmyah to streamline its commercial and retail operations into one system and effectively manage its portfolio from leasing and reporting to forecasting and accounting. Yardi will also help deliver a self-service portal and app, improving convenience and accessibility for tenants to update details, manage maintenance and view sales metrics. With a more unified system in place, Tanmyah can enhance staff productivity, tenant relations and maximise return on assets.
“We’re thrilled to implement Yardi’s cloud technology into our operations and enhance our ability to deliver exceptional services to all our stakeholders,” expressed Mutaz Alattas, property management and leasing manager for Tanmyah. “With Yardi as our central solution, we will be positioned to efficiently manage our expansive commercial and retail portfolio and become one of the top choices for management and development within the region.”
“Yardi’s unified technology is purpose-built to cater to the strategic expansion and evolving needs of businesses such as Tanmyah,” noted Said Haider, senior director of middle east sales for Yardi®. “We are delighted to contribute to the progression of Tanmyah and are excited about the prospects of our partnership.”
See how Yardi can boost your commercial portfolio activities with a cloud-based management platform.
About TanmyahAdvanced Development Real Estate Investments Company Ltd., known as Tanmyah, is a Saudi Company based in Jeddah on the Western Coast of Saudi Arabia. Tanmyah is recognised as one of the early pioneers in property management and development in the region due to its historic achievements in the real estate market coupled with the generous contributions by its founders to the local community. For more information, visit tanmyah.com.sa.
About YardiCelebrating its 40-year anniversary in 2024, Yardi® develops and supports industry-leading investment and property management software for all types and sizes of real estate companies. With over 9,000 employees, Yardi is working with clients globally to drive significant innovation in the real estate industry. For more information on how Yardi is Energised for Tomorrow, visit yardi.ae.
Photo – https://mma.prnewswire.com/media/2406896/Tanmyah_Yardi.jpgLogo – https://mma.prnewswire.com/media/737275/Yardi_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/tanmyah-to-unify-management-processes–boost-investment-value-with-yardi-cloud-technology-302138489.html

Continue Reading

Trending